103 related articles for article (PubMed ID: 7910207)
1. Inactivated HIV-1 Immunogen: impact on markers of disease progression.
Moss RB; Ferré F; Trauger R; Jensen F; Daigle A; Richieri SP; Carlo DJ
J Acquir Immune Defic Syndr (1988); 1994; 7 Suppl 1():S21-7. PubMed ID: 7910207
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a gp120-depleted, inactivated HIV-1 immunogen: results of a double-blind, adjuvant controlled trial.
Trauger RJ; Daigle AE; Giermakowska W; Moss RB; Jensen F; Carlo DJ
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S74-82. PubMed ID: 7552517
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic analysis of human immunodeficiency virus (HIV) type 1 cell-mediated immune responses after treatment with an HIV-1 immunogen.
Moss RB; Wallace MR; Giermakowska WK; Webb E; Savary J; Chamberlin-Brandt C; Theofan G; Musil R; Richieri SP; Jensen FC; Carlo DJ
J Infect Dis; 1999 Sep; 180(3):641-8. PubMed ID: 10438350
[TBL] [Abstract][Full Text] [Related]
4. Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 Immunogen: long-term follow-up.
Levine AM; Groshen S; Allen J; Munson KM; Carlo DJ; Daigle AE; Ferre F; Jensen FC; Richieri SP; Trauger RJ; Parker JW; Salk PL; Salk J
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Apr; 11(4):351-64. PubMed ID: 8601221
[TBL] [Abstract][Full Text] [Related]
5. Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells.
Trauger RJ; Ferre F; Daigle AE; Jensen FC; Moss RB; Mueller SH; Richieri SP; Slade HB; Carlo DJ
J Infect Dis; 1994 Jun; 169(6):1256-64. PubMed ID: 7910836
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of HIV-seropositive patients: preliminary report on a dose-ranging study.
Slade H; Turner J; Abrams C; Carlo D; Salk J
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1329-31. PubMed ID: 1361349
[No Abstract] [Full Text] [Related]
7. Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE) in human immunodeficiency virus type-1 seropositive subjects.
Moss RB; Giermakowska W; Lanza P; Turner JL; Wallace MR; Jensen FC; Theofan G; Richieri SP; Carlo DJ
Viral Immunol; 1997; 10(4):221-8. PubMed ID: 9473153
[TBL] [Abstract][Full Text] [Related]
8. The effects of an HIV-1 immunogen (Remune) on viral load, CD4 cell counts and HIV-specific immunity in a double-blind, randomized, adjuvant-controlled subset study in HIV infected subjects regardless of concomitant antiviral drugs.
Turner JL; Kostman JR; Aquino A; Wright D; Szabo S; Bidwell R; Goodgame J; Daigle A; Kelley E; Jensen F; Duffy C; Carlo D; Moss RB
HIV Med; 2001 Apr; 2(2):68-77. PubMed ID: 11737381
[TBL] [Abstract][Full Text] [Related]
9. Early clinical markers and CD4 percentage in subjects with human immunodeficiency virus infection.
Wallace MR; Moss RB; Beecham HJ; Grace CJ; Hersh EM; Peterson E; Murphy R; Shepp DH; Siegal FP; Turner JL; Safrin S; Carlo DJ; Levine AM
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Aug; 12(4):358-62. PubMed ID: 8673544
[TBL] [Abstract][Full Text] [Related]
10. A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects.
Peters BS; Cheingsong-Popov R; Callow D; Foxall R; Patou G; Hodgkin K; Weber JN
J Infect; 1997 Nov; 35(3):231-5. PubMed ID: 9459393
[TBL] [Abstract][Full Text] [Related]
11. A randomized, placebo-controlled, blind anti-AIDS clinical trial: safety and immunogenicity of a specific anti-IFN alpha immunization.
Gringeri A; Santagostino E; Mannucci PM; Tradati F; Cultraro D; Buzzi A; Criscuolo M; David A; Guillemot L; Barré-Sinoussi F
J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):978-88. PubMed ID: 7914235
[TBL] [Abstract][Full Text] [Related]
12. Salk's HIV immunogen: an immune-based therapy in human trials since 1988.
Crit Path AIDS Proj; 1994-1995 Winter; (No 30):1, 20-3. PubMed ID: 11362152
[TBL] [Abstract][Full Text] [Related]
13. A double-blind, adjuvant-controlled trial of human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) monotherapy in asymptomatic, HIV-1-infected thai subjects with CD4-cell counts of >300.
Churdboonchart V; Sakondhavat C; Kulpradist S; Na Ayudthya BI; Chandeying V; Rugpao S; Boonshuyar C; Sukeepaisarncharoen W; Sirawaraporn W; Carlo DJ; Moss R
Clin Diagn Lab Immunol; 2000 Sep; 7(5):728-33. PubMed ID: 10973445
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 10(6)/L CD4 cell counts: A randomized controlled trial.
Kahn JO; Cherng DW; Mayer K; Murray H; Lagakos S
JAMA; 2000 Nov; 284(17):2193-202. PubMed ID: 11056590
[TBL] [Abstract][Full Text] [Related]
15. Cell-associated HIV-1 messenger RNA and DNA in T-helper cell and monocytes in asymptomatic HIV-1-infected subjects on HAART plus an inactivated HIV-1 immunogen.
Patterson BK; Carlo DJ; Kaplan MH; Marecki M; Pawha S; Moss RB
AIDS; 1999 Sep; 13(13):1607-11. PubMed ID: 10509560
[TBL] [Abstract][Full Text] [Related]
16. HIV-1-Specific CD4 helper function in persons with chronic HIV-1 infection on antiviral drug therapy as measured by ELISPOT after treatment with an inactivated, gp120-depleted HIV-1 in incomplete Freund's adjuvant.
Moss RB; Webb E; Giermakowska WK; Jensen FC; Savary JR; Wallace MR; Carlo DJ
J Acquir Immune Defic Syndr; 2000 Jul; 24(3):264-9. PubMed ID: 10969351
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of HIV type 1 antigen-specific CD4+ T cell memory in subjects with chronic HIV type 1 infection receiving an HIV type 1 immunogen.
Maino VC; Suni MA; Wormsley SB; Carlo DJ; Wallace MR; Moss RB
AIDS Res Hum Retroviruses; 2000 Apr; 16(6):539-47. PubMed ID: 10777144
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators.
Kelleher AD; Roggensack M; Jaramillo AB; Smith DE; Walker A; Gow I; McMurchie M; Harris J; Patou G; Cooper DA
AIDS; 1998 Jan; 12(2):175-82. PubMed ID: 9468366
[TBL] [Abstract][Full Text] [Related]
19. Immunologic markers of progression to acquired immunodeficiency syndrome are time-dependent and illness-specific.
Krämer A; Biggar RJ; Hampl H; Friedman RM; Fuchs D; Wachter H; Goedert JJ
Am J Epidemiol; 1992 Jul; 136(1):71-80. PubMed ID: 1384311
[TBL] [Abstract][Full Text] [Related]
20. Effect of HIV-specific immune-based therapy in subjects infected with HIV-1 subtype E in Thailand.
Churdboonchart V; Moss RB; Sirawaraporn W; Smutharaks B; Sutthent R; Jensen FC; Vacharak P; Grimes J; Theofan G; Carlo DJ
AIDS; 1998 Aug; 12(12):1521-7. PubMed ID: 9727574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]